WS Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

WS Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-30,953	Closed	-$2.98M	–	56
2023 Q4	$2.98M	Hold	30,953	–	–	0.18%	55
2023 Q3	$2.74M	Hold	30,953	–	–	0.22%	58
2023 Q2	$2.68M	Hold	30,953	–	–	0.22%	51
2023 Q1	$3.01M	Hold	30,953	–	–	0.32%	45
2022 Q4	$3.2M	Hold	30,953	–	–	0.27%	53
2022 Q3	$2.62M	Hold	30,953	–	–	0.24%	52
2022 Q2	$2.56M	Hold	30,953	–	–	0.21%	54
2022 Q1	$2.39M	Hold	30,953	–	–	0.12%	56
2021 Q4	$2.73M	Hold	30,953	–	–	0.22%	48
2021 Q3	$2.39M	Hold	30,953	–	–	0.25%	52
2021 Q2	$2.58M	Hold	30,953	–	–	0.25%	57
2021 Q1	$2.34M	Sell	30,953 -1,453	-4%	-$119K	0.24%	49
2020 Q4	$2.84M	Hold	32,406	–	–	0.3%	40
2020 Q3	$2.46M	Hold	32,406	–	–	0.27%	45
2020 Q2	$4M	Sell	32,406 -5,803	-15%	-$577K	0.49%	37
2020 Q1	$3.23M	Sell	38,209 -1,987	-5%	-$171K	0.35%	42
2019 Q4	$3.4M	Hold	40,196	–	–	0.29%	44
2019 Q3	$2.71M	Sell	40,196 -4,579	-10%	-$353K	0.21%	51
2019 Q2	$3.83M	Sell	44,775 -5,467	-11%	-$468K	0.25%	53
2019 Q1	$4.46M	Sell	50,242 -6,936	-12%	-$643K	0.27%	50
2018 Q4	$4.87M	Sell	57,178 -8,122	-12%	-$773K	0.24%	50
2018 Q3	$6.33M	Hold	65,300	–	–	0.21%	54
2018 Q2	$6.15M	Buy	+65,300	New	+$5.72M	0.17%	55

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

WS Management's BMRN Position: Q1 2024 in Review

WS Management sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2024, closing a stake of 30,953 shares — an estimated $2.98M sold.

WS Management first reported a position in BMRN in Q2 2018 and held it in 23 quarters. The position peaked at $6.33M in Q3 2018. 560 funds tracked by Wall St. Rank hold BMRN as of Q1 2024.

WS Management reported no remaining BioMarin Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
WS Management sold 30,953 BioMarin Pharmaceuticals shares in Q1 2024, an estimated $2.98M.
WS Management first reported a position in BioMarin Pharmaceuticals in Q2 2018 and held it in 23 quarters.
WS Management's BioMarin Pharmaceuticals position peaked at $6.33M in Q3 2018.
560 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2024.

Based on WS Management's 13F filing for Q1 2024, filed 14 May 2024.